Business & regional news

Company recognized among top 52 global companies making positive social impact through core business strategy

Symplicity Spyral is the first renal denervation technology to be approved by the National Medical Products Administration; new, innovative, minimally invasive procedure uses radiofrequency energy to help reduce high blood pressure

Medtronic today announced it received a license from Health Canada for its Symplicity Spyral™ multi-electrode Renal Denervation (RDN) System. This is indicated for the management of essential...

Bifurcation using Onyx Frontier DES Medtronic announced today that it has received Food and Drug Administration (FDA) approval for the treatment of non-left main bifurcation lesions utilizing the...

Medtronic announced today that it has launched its newest drug-eluting coronary stent, the Onyx Frontier™ drug-eluting stent (DES), following recent CE Mark approval. The Onyx Frontier DES...